PMID: 3383988Jan 1, 1988Paper

Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide

European Journal of Clinical Pharmacology
D J BackB K Park

Abstract

The effects of sulphaphenazole, cimetidine and primaquine on the disposition of antipyrine and tolbutamide in healthy volunteers have been investigated. The model substrates were administered simultaneously in order more clearly to define any selective effects of the potential inhibitors. Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1). Clearance to hydroxytolbutamide (OHTOL) and carboxytolbutamide (COOHTOL) was also significantly decreased. In contrast, sulphaphenazole had no effect on the disposition of antipyrine. Administration of cimetidine did not significantly alter the disposition of either model drug. However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively). Clearance to OHTOL and hydroxymethylantipyrine (HMA) was reduced. A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 t...Continue Reading

References

Mar 1, 1979·British Journal of Clinical Pharmacology·J R IdleR L Smith
Jun 13, 1979·Biochemical and Biophysical Research Communications·P BeauneJ P Leroux
Nov 1, 1977·Clinical Pharmacology and Therapeutics·S M PondD N Wade
Jun 1, 1975·Clinical Pharmacology and Therapeutics·B LumholtzJ M Hansen
Jan 1, 1987·European Journal of Clinical Pharmacology·W Kalow
Mar 1, 1987·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·F P GuengerichR S Lloyd
May 1, 1987·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A AdedoyinJ B Houston
Aug 1, 1987·British Journal of Clinical Pharmacology·H S PurbaM L Orme
May 1, 1986·Journal of Clinical Pharmacology·E W CateJ R Powell
Oct 1, 1986·Chemico-biological Interactions·J H Riviere, D J Back
Jan 1, 1986·European Journal of Clinical Pharmacology·C StockleyA Somogyi
Mar 1, 1987·Clinical Pharmacology and Therapeutics·E SpinaF Sjöqvist
Mar 1, 1987·Clinical Pharmacology and Therapeutics·B Osikowska-EversM Eichelbaum
Jan 1, 1987·European Journal of Clinical Pharmacology·B GachályiA Káldor
Jan 1, 1973·Pharmacology·D H HuffmanD L Azarnoff
Mar 1, 1982·Clinical Pharmacology and Therapeutics·K J BreenR G Shaw
Nov 1, 1982·British Journal of Clinical Pharmacology·B K Park
Jan 1, 1984·European Journal of Clinical Pharmacology·A Küpfer, R Preisig
Oct 1, 1983·British Journal of Clinical Pharmacology·N G DeyA McBurney
Oct 1, 1983·British Journal of Clinical Pharmacology·D B BackS N Newby
Jan 1, 1983·European Journal of Clinical Pharmacology·M DøssingH E Poulsen
Nov 1, 1983·British Journal of Clinical Pharmacology·D J BackM L Orme
Jun 1, 1984·Clinical Pharmacology and Therapeutics·R DahlqvistF Sjöqvist
Jan 15, 1983·Biochemical Pharmacology·D J BackA M Breckenridge
Jan 1, 1982·Clinical Pharmacokinetics·M Eichelbaum
Mar 1, 1982·British Journal of Clinical Pharmacology·M DanhofD D Breimer
Jan 1, 1982·European Journal of Clinical Pharmacology·J O MinersD J Birkett

❮ Previous
Next ❯

Citations

Jan 1, 1993·European Journal of Clinical Pharmacology·H MönigH M Schulte
Oct 1, 1978·Journal of Steroid Biochemistry·B K Park
Jan 1, 1989·Pharmacology & Therapeutics·D J Back, M L Orme
Aug 26, 1998·Journal of Biochemical and Biophysical Methods·Y K Leung, J W Ho
Jul 15, 1998·British Journal of Clinical Pharmacology·J O Miners, D J Birkett
Jun 1, 1991·British Journal of Clinical Pharmacology·M A PageG M Shenfield
Jul 1, 1994·British Journal of Clinical Pharmacology·V SpaldinB K Park
Feb 12, 2004·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·J L C M DorneA G Renwick
Nov 1, 1996·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·W M Zweers-ZeilmakerR F Witkamp
Nov 1, 1990·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·B K Park, N R Kitteringham
Jan 30, 2004·Journal of Clinical Pharmacology·Honghui ZhouJames F McLeod
Jan 13, 2018·The Journal of Pharmacology and Experimental Therapeutics·Yi-An BiManthena V S Varma
Jun 26, 1999·British Journal of Clinical Pharmacology·D J CarlileJ B Houston
Jul 30, 2020·Clinical Pharmacokinetics·Jasleen K SodhiLeslie Z Benet
Nov 10, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Everett J PerkinsChris Twelves

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.